Analyst Michael Ryskin of Bank of America Securities maintained a Buy rating on Zoetis, with a price target of $200.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ryskin has given his Buy rating due to a combination of factors, including the recent positive opinion from the CVMP on Zoetis’s long-acting monoclonal antibodies for osteoarthritic pain in pets. This positive opinion is a significant step towards EU approval and anticipated launch in the first half of 2026, with similar expectations for the US market.
The introduction of these new products, Lenivia and Portela, is crucial for Zoetis as they aim to address safety concerns associated with their existing product, Librela. By targeting a different binding site on the protein, these new antibodies are expected to mitigate previous safety issues. The company plans a targeted launch strategy to build awareness among key opinion leaders and specialists, which is expected to gradually improve market sentiment and contribute positively to Zoetis’s growth, despite potential initial sales cannibalization.
ZTS’s price has also changed slightly for the past six months – from $147.000 to $141.110, which is a -4.01% drop .